Eupraxia Pharmaceuticals (EPRX) Current Assets (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Current Assets data on file, last reported at $142.1 million in Q1 2026.

• On a quarterly basis, Current Assets rose 396.83% year-over-year to $142.1 million in Q1 2026; TTM through Mar 2026 was $142.1 million, a 396.83% increase from a year earlier, with the FY2025 full-year figure at $85.1 million, up 147.12% from the prior year.
• Current Assets for Q1 2026 stood at $142.1 million, up from $85.1 million in the prior quarter.
• Over the last five years, Current Assets for EPRX reached as high as $142.1 million in Q1 2026 and fell as low as $9.9 million in Q3 2024.
• Historically, Current Assets has averaged $46.7 million across 5 years, with a median of $28.6 million in 2025.
• On a YoY basis, Current Assets climbed as much as 824.17% in 2025 and fell as far as 21.01% in 2025.
• Year by year, Current Assets stood at $18.6 million in 2022, then advanced by 6.53% to $19.8 million in 2023, then surged by 73.9% to $34.4 million in 2024, then surged by 147.12% to $85.1 million in 2025, then surged by 67.01% to $142.1 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $142.1 million in Q1 2026, $85.1 million in Q4 2025, and $91.4 million in Q3 2025.